TUESDAY, Dec. 13, 2022 (HealthDay Information) — Females are underrepresented in COVID-19 therapy trials, whereas Asian and Black people are underrepresented in COVID-19 prevention trials, based on a assessment revealed on-line Dec. 5 in JAMA Inner Medication.
Hong Xiao, Ph.D., from the Fred Hutchinson Most cancers Heart in Seattle, and colleagues performed a scientific literature assessment to evaluate illustration of individuals in COVID-19 trials.
Utilizing knowledge from 122 U.S.-based COVID-19 medical trials (176,654 individuals), the researchers discovered that estimated illustration in prevention and therapy trials versus the U.S. inhabitants with COVID-19 was 48.9 and 44.6 % versus 52.4 % for feminine individuals; 23.0 and 36.6 % versus 17.7 % for Hispanic or Latino individuals; 7.2 and 16.5 % versus 14.1 % for Black individuals; 3.8 and 4.6 % versus 3.7 % for Asian individuals; 0.2 and 0.9 % versus 0.2 % for Native Hawaiian or Different Pacific Islander individuals; and 1.3 and 1.4 % versus 1.1 % for American Indian or Alaska Native individuals. Feminine individuals had been underrepresented in therapy trials (85.1 % of anticipated), whereas Black individuals (53.7 % of anticipated) and Asian individuals (64.4 % of anticipated) had been underrepresented in prevention trials in contrast with anticipated charges within the COVID-19 reference inhabitants. Hispanic or Latino individuals had been overrepresented in therapy trials (206.8 % of anticipated).
“Methods to higher guarantee numerous illustration in COVID-19 research are wanted, particularly for prevention trials,” the authors write.
Copyright © 2022 HealthDay. All rights reserved.
